Compare
Up to five products, technologies, targets, trials, or cancers side by side, same fields, differences highlighted. The URL is shareable.
Up to five products, technologies, targets, trials, or cancers side by side, same fields, differences highlighted. The URL is shareable.
| Field | TreatmentApproved Sacituzumab govitecan The first TROP2-targeted ADC. It delivers a strong chemotherapy directly to breast and bladder cancer cells and is now a first-line option in triple-negative breast cancer. | TreatmentApproved Datopotamab deruxtecan Datopotamab deruxtecan (Datroway) is the second TROP2 ADC and shares Enhertu's payload. In 2026 it became a first-line option for triple-negative breast cancer patients who cannot receive immunotherapy. | TreatmentApproved Sacituzumab tirumotecan Sacituzumab tirumotecan is Kelun-Biotech's TROP2 ADC, approved in China in 2024 for pretreated triple-negative breast cancer and then EGFR-mutant lung cancer. Merck holds rights outside Greater China and runs the TroFuse programme of more than ten phase 3 trials across breast, lung, endometrial and cervical cancer; in the US it holds a priority voucher but no approval yet. |
|---|---|---|---|
| Brand / code• | Trodelvy · IMMU-132 | Datroway · Dato-DXd, DS-1062 | sac-TMT, MK-2870, SKB264 |
| Modality | ADC | ADC | ADC |
| Mechanism• | Humanised anti-TROP2 IgG1 (hRS7) internalised; SN-38 released by linker hydrolysis inside and around tumour cells. | Humanised anti-TROP2 IgG1 with DXd; internalisation, lysosomal release, TOP1 inhibition, bystander effect. | Anti-TROP2 IgG1 with a stable, irreversibly-conjugated linker and a belotecan-derived TOP1 payload with reported lower efflux-pump susceptibility. |
| Payload• | SN-38 (topoisomerase-I inhibitor), DAR ~7.6 | DXd (TOP1 inhibitor), DAR ~4 | T030 (belotecan-derived TOP1 inhibitor), DAR ~7.4 |
| Linker• | CL2A, pH-sensitive cleavable | Tetrapeptide GGFG, cleavable | Sulfonyl pyrimidine (CL2A-like), pH-sensitive and enzyme-cleavable |
| Targets | TROP2 | TROP2 | TROP2 |
| Cancers• | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, Bladder & urothelial cancer, Metastatic triple-negative breast cancer | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer, Metastatic triple-negative breast cancer, EGFR-mutated non-small-cell lung cancer, PD-L1-high non-small-cell lung cancer without a driver mutation | Triple-negative breast cancer (TNBC), Non-small-cell lung cancer, HR-positive / HER2-negative breast cancer, Endometrial cancer, Cervical cancer |
| Companies• | Gilead Sciences (incl. Kite) | Daiichi Sankyo, AstraZeneca | Sichuan Kelun-Biotech, Merck & Co. (MSD) |
| First approval• | 2020 | 2025 | 2024 |
| Approvals• | US 2020: Metastatic TNBC, ≥2 prior lines (accelerated; full 2021) · US 2023: HR+/HER2- metastatic breast cancer after endocrine therapy and ≥2 chemotherapies · US 2026: First-line metastatic TNBC: monotherapy (PD-1 ineligible) or with pembrolizumab (PD-L1 CPS ≥10) · EU 2021: mTNBC ≥2 lines; HR+ 2023 | US 2025: HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy · US 2025: EGFR-mutant NSCLC after EGFR TKI and platinum chemotherapy · US 2026: First-line unresectable/metastatic TNBC, PD-1/PD-L1 inhibitor ineligible · EU 2025: HR+/HER2- mBC after endocrine + chemo; 4 Apr 2025 | China 2024: Pretreated advanced TNBC; later EGFR-mutant NSCLC after TKI |
| Dosing• | IV infusion; 10 mg/kg on days 1 and 8 of each 21-day cycle; monitor: Blood counts each dose; UGT1A1*28 homozygotes have earlier and more frequent neutropenia; anti-emetic premedication | IV infusion; 6 mg/kg (maximum 540 mg for ≥90 kg) every 3 weeks; monitor: Oral care with steroid mouthwash prophylaxis; baseline and periodic eye examination; respiratory symptoms | IV infusion; 5 mg/kg every 2 weeks (China label, TNBC); phase 3 trials use 4 mg/kg every 2 weeks in combination regimens; monitor: Blood counts; stomatitis and ocular surface care |
| Grade ≥3 toxicities• | Neutropenia 49% · Anaemia 9% · Fatigue 6% · Diarrhoea 11% · Nausea 3.1% · Alopecia 0% · Constipation 0.4% · Vomiting 1.6% · Decreased appetite 1.6% · Rash 0.4% | Stomatitis 7% · Nausea 1.4% · Fatigue 4.2% · Alopecia 0% · Constipation 0.3% · Dry eye 0.8% · Keratitis 1.1% · Vomiting 1.1% | - |
| Access• | US: Medicare Part B (physician-administered); commercial plans per formulary · UK: NICE: recommended for pretreated metastatic TNBC (TA819) and HR+/HER2- breast cancer after endocrine therapy and chemotherapy · EU: EMA approved; national reimbursement varies | US: Medicare Part B (physician-administered); commercial plans per formulary · UK: NICE: appraisal in progress for HR+/HER2- breast cancer; not yet recommended (2026) | CN: NMPA approved 2024; National Reimbursement Drug List inclusion from 2025 · US: Investigational; not yet approved |
| Regulatory events• | 2016-02-05 designation (US) · 2020-04-22 approval (US) · 2021-04-07 approval (US) · 2021-11-22 approval (EU) · 2023-02-03 approval (US) · 2024-11 withdrawal (US) · 2026-Q2 approval (US) | 2025-01-17 approval (US) · 2025-03 approval (JP) · 2025-06-23 approval (US) · 2026-Q2 approval (US) | 2022-05 filing (China) · 2024-11 approval (China) · 2024-12-03 designation (US) · 2025-03 approval (China) · 2026-07 designation (US) |
| Key trials• | ASCENT, ASCENT-03, ASCENT-04 / KEYNOTE-D19, Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer, Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im, Study of Novel Treatment Combinations in Patients With Lung Cancer, Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC), A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer, Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread, Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy, Study of Sacituzumab Govitecan in Patients With Solid Tumor, Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46), Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors, Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments, Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors, Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC), A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley), A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors | TROPION-Breast01, TROPION-Breast02, TROPION-Breast05, TROPION-Lung01, Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L, A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C, A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan, Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab, Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07), Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥, Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti, A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC), Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies, Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer, Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03), Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations, A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors, Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies, A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02), A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan, Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A, A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer, A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc, A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021), A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl, A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015), Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P, A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With, Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287, A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P, A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm, A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan, Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005), A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients, Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With, Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01), SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer., A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-, Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto, A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A), A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04), Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012), Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06), KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J), A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010), A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031), A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032), A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F), A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B), A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027), Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma, Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06), Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06), Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01), A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) |
Rows marked • differ between the selected items. Fields come from the OnCo records; an empty field shows a dash. To fill a gap, use the suggest-an-edit form on that record's page.